...
首页> 外文期刊>Journal of Translational Medicine >Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
【24h】

Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study

机译:分析血浆中富含器官的microRNA作为开发通用筛选测试的一种方法:可行性研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Early disease detection with a minimally invasive screening test will significantly increase effectiveness and decrease the cost of treatment. Here we propose a framework of a novel approach – Universal Screening Test (UST) for the detection of pathological processes in a particular organ system, organ, or tissue by RT-qPCR analysis of circulating cell-free miRNAs in plasma. As the first step towards assessing the feasibility of this concept, the present study was designed to analyze whether the same microRNAs (miRNAs) can detect various diseases of a particular organ system. Methods RNA was extracted from plasma using Trizol treatment and silica binding. Levels of miRNAs were measured by single target RT-qPCR. The following innovations have been tested and proven effective: (i) the use of organ system/organ/tissue-enriched miRNAs; (ii) the use of miRNAs associated with broad disease categories, such as cancer and inflammation, in combination with the organ-enriched miRNAs; and (iii) the use of “miRNA pairs” for selecting miRNA combinations with the highest sensitivity and specificity. Results Here we report biomarker miRNA pairs effectively differentiating (i) patients with pulmonary system diseases (asthma, pneumonia and non-small cell lung cancer) and gastrointestinal (GI) system diseases (Crohn’s disease, stages I/II esophageal, gastric and colon cancers) from controls, each with 95% accuracy; (ii) patients with a pathology of the pulmonary system from patients with a pathology of the GI system with 94% accuracy; and (iii) cancer patients (stages I/II esophageal, gastric, colon cancers, or non-small cell lung cancer) from patients with inflammatory diseases (asthma, pneumonia, or Crohn’s disease) with 93%-95% accuracy. Conclusions The results obtained in the present study, along with the data reported by us and others previously, are encouraging and lay the ground for further investigation of the described approach for UST development.
机译:背景技术采用微创筛查试验的早期疾病检测将显着提高疗效并降低治疗成本。在这里,我们提出了一种新方法的框架-通用筛选测试(UST),用于通过血浆中循环无细胞miRNA的RT-qPCR分析检测特定器官系统,器官或组织中的病理过程。作为评估此概念可行性的第一步,本研究旨在分析相同的microRNA(miRNA)是否可以检测特定器官系统的各种疾病。方法采用Trizol处理和硅胶结合从血浆中提取RNA。通过单个靶标RT-qPCR测量miRNA的水平。下列创新已被测试并证明有效:(i)使用器官系统/富含器官/组织的miRNA; (ii)将与广泛疾病类别(例如癌症和炎症)相关的miRNA与富含器官的miRNA结合使用; (iii)使用“ miRNA对”选择灵敏度和特异性最高的miRNA组合。结果在这里,我们报告了生物标记物miRNA对可有效地区分(i)患有肺系统疾病(哮喘,肺炎和非小细胞肺癌)和胃肠道(GI)系统疾病(克罗恩病,I / II期食管,胃癌和结肠癌)的患者),每个控件的准确率均达到95%; (ii)胃肠道系统疾病患者的肺系统病理学患者,准确率为94%; (iii)来自炎症性疾病(哮喘,肺炎或克罗恩病)患者的癌症患者(I / II期食管,胃,结肠癌或非小细胞肺癌),准确度为93%-95%。结论在本研究中获得的结果,以及我们和其他人先前报告的数据,令人鼓舞,并为进一步研究所述的UST开发方法奠定了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号